2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4707 Outcomes associated with routine bronchodilator use in adults with sickle cell disease hospitalized for acute chest syndrome: A retrospective cohort study

Richard Wu, MD, Vennela Pandaraboyina, MD2, Rachel Kimura, MD3
1 Boston Medical Center, Boston, United States
2 Boston Medical Center, Boston, United States
3 Boston Medical Center, Boston, United States

Background: Acute chest syndrome (ACS) is a severe complication and major cause of death in sickle cell disease defined by the onset of new pulmonary symptoms and findings on chest imaging. In most cases, a cause for ACS is not readily identified, but infection, pulmonary infarctions, and fat emboli are triggers that are frequently observed in clinical practice. The role of bronchial hyperreactivity in ACS is unclear, but bronchodilator use remains common despite a paucity of literature evaluating its effects on patient outcomes. Routine bronchodilator use adds to the cost of care and may cause unwanted cardiovascular and psychiatric side effects. Identifying a signal for harm or benefit can better clarify the utility of this treatment in patients with ACS.

Methods: We conducted a real-world retrospective cohort study utilizing the TriNetX Research Network database, a multicenter federated electronic health record platform including de-identified data from 112 healthcare organizations. Adults aged 18 years or older with an inpatient admission between January 1st, 2000 to January 1st, 2026 for acute chest syndrome were eligible for inclusion. The intervention group received albuterol, levalbuterol, ipratropium, or a combined albuterol/ipratropium bronchodilator within two days of admission while the comparison group did not receive any bronchodilators within the first two days. Patients who died within two days of admission were excluded and a landmark time of day two was set for analysis. Propensity matching was conducted using 1:1 greedy nearest-neighbor matching based on demographic data, chronic comorbidities including asthma, utilization of exchange or simple transfusions, utilization of critical care services or ventilators, and prior use of bronchodilators within the 90 day period prior to inclusion. The primary outcome of interest is mortality at 90 days and secondary outcomes evaluated included escalation of care as defined by new utilization of critical care services, and a new requirement for mechanical ventilation.

Results: 3,418 patients in the bronchodilator cohort and 5,235 patients in the no bronchodilator cohort met criteria for inclusion. After propensity matching, 3,112 patients remained in each cohort. 688 patients in the bronchodilator cohort (22.1%) and 742 patients in the no bronchodilator cohort (15.7%) had asthma prior to matching. After matching, 682 (21.9%) and 685 (22.0%) respectively remained. No statistically significant difference in mortality was observed at 90 days between the two cohorts (HR 0.94, 95% CI 0.60 - 1.47; p = 0.7789). Similarly, no difference in escalation of care (HR 1.17, 95% CI 0.94 - 1.46; p = 0.1611) or mechanical ventilation (HR 0.99, 95% 0.71 - 1.36; p - 0.9312) was observed.

Conclusion: This large, multicenter retrospective real-world study suggests that routine use of bronchodilators in patients hospitalized with ACS does not provide a benefit to mortality or to the morbidity metrics of escalation of care and utilization of mechanical ventilation in adult patients at 90 days. There remains a lack of prospective research on the effects of bronchodilator use in sickle cell patients presenting with ACS and this analysis represents one of the first and largest studies that we are aware of evaluating its efficacy. There remains an urgent need for well-designed prospective studies to better understand the utility of bronchodilators in this underserved population and to ultimately establish best practices around their usage. Further delineating whether bronchodilators may provide a patient-centric benefit to symptoms that cannot be evaluated in a retrospective electronic health record database is worthwhile as well in adding to the overall cost-benefit analysis and can be considered for future studies.

Richard Wu, MD: No relevant conflicts of interest to declare.